Results 31 to 40 of about 26,068 (276)

Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome [PDF]

Current Hypertension Reports, 2010
Key components of the metabolic syndrome (MetS), ie, obesity and insulin resistance, are associated with increased aldosterone production and mineralocorticoid receptor (MR) activation. Both MetS and hyperaldosteronism are proinflammatory and pro-oxidative states associated with cardiovascular disease.
Amir, Tirosh, Rajesh, Garg, Gail K, Adler   +2 more
openaire   +2 more sources

Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release [PDF]

, 2007
We investigated the effect of the glucocorticoid receptor (GR) antagonist Org 34850 on fast and delayed inhibition of corticosterone secretion in response to the synthetic glucocorticoid methylprednisolone (MPL).
Craighead, Mark, Grassie, Morag, Harrison, Louse R., Lightman, Stafford L., MacSweeney, Cliona P., Spiga, Francesca, Thomson, Fiona .J., Wood, Susan A.   +7 more
core   +1 more source

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review

Consilium Medicum, 2022
Mineralocorticoid receptor antagonists (MRAs) are part of basic medical therapy for heart failure. The clinical efficacy of MRAs has been proven by randomized clinical trials. To review comparative efficacy and tolerability data between the two main MRAs,
Natalia V. Safronova, Igor V. Zhirov, Sergey N. Tereshchenko   +2 more
doaj   +1 more source

Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure [PDF]

, 2014
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/102661/1/ejhf31 ...
Beck, Borlaug, Brilla, Burgess, Böhm, Chai, Chapman, Chatterjee, Cheng, Croom, Davies, Desai, Deswal, Edelmann, Fagart, Flack, Fletcher, Gardiner, Gasparo, Gerstein, Hernandez, Hollenberg, Iqbal, Jessup, Jeunemaitre, Joffe, Karagiannis, Kosmala, Krum, Kursaklioglu, Mak, Mansia, Maron, Martyniuk, McKelvie, McKenna, McKenna, McMurray, Michea, Parthasarathy, Pitt, Pitt, Pitt, Preiss, Ramirez-Gil, Rose, Saruta, Sato, Savoia, Sternon, Struthers, Swaminathan, Tamirisa, Tomova, Van Belle, Wakabayashi, Ward, Wei, Weinberger, White, Yamaji, Yamanaka, Yee, Zannad, Zannad, Zannad   +65 more
core   +2 more sources

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice

Frontiers in Physiology, 2022
Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production.
Roberto Palacios-Ramirez, Ixchel Lima-Posada, Benjamin Bonnard, Marie Genty, Amaya Fernandez-Celis, Judith Hartleib-Geschwindner, Fabienne Foufelle, Natalia Lopez-Andres, Krister Bamberg, Frederic Jaisser, Frederic Jaisser   +10 more
doaj   +1 more source

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction:findings from BIOSTAT-CHF [PDF]

, 2017
Aims Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice.
Agrinier, Albert, Azizi, Bostick, Bozkurt, Cooper, Curtis, Dev, Dev, Dickstein, Elze, Epstein, Erhardt, Eschalier, Ferreira, Fonarow, Ghali, Gheorghiade, Hernandez, Juurlink, Kalidindi, Lachaine, Lam, Levey, Maggioni, Maggioni, Maggioni, Margolis, Masoudi, McMurray, Olivier, Pitt, Pitt, Pitt, Ponikowski, Postmus, Raebel, Rossignol, Rossignol, Rossignol, Shah, Takeda, Vardeny, Vardeny, Voors, Williams, Williams, Zannad, Zannad, Zannad   +49 more
core   +5 more sources

The ICD in heart failure - time for a rethink? [PDF]

, 2016
No abstract ...
McMurray, John J.V.
core   +1 more source

Heart failure: the role for mineralocorticoid receptor antagonists

Swiss Medical Weekly, 2014
Mineralocorticoid receptor antagonists (MRA’s) have been shown to be effective in patients with HFREF while their role in patients with HFPEF remains controversial. Despite a class  one indication in both the ESC and AHA/ACC heart failure guidelines
Bertram Pitt
doaj   +1 more source

Temporal and spatial dynamics of corticosteroid receptor down-regulation in rat brain following social defeat [PDF]

, 2001
The experiments explored the nature and time course of changes in glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) binding in homogenates of various brain regions and pituitary of male Wistar rats following social defeat stress.
Boer, Sietse F. de,, Bohus, Béla,, Buwalda, Bauke,, Felszeghy, Klára,, Horváth, Katalin M.,, Koolhaas, Jaap M.,, Nyakas, Csaba,   +6 more
core   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources